Outlook Therapeutics (OTLK) Gross Profit: 2015-2020
Historic Gross Profit for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$19,031.
- Outlook Therapeutics' Gross Profit fell 100.33% to -$19,031 in Q3 2020 from the same period last year, while for Sep 2020 it was -$1.8 million, marking a year-over-year decrease of 121.56%. This contributed to the annual value of -$3.2 million for FY2024, which is 24.72% down from last year.
- As of Q3 2020, Outlook Therapeutics' Gross Profit stood at -$19,031, which was up 95.71% from -$443,624 recorded in Q2 2020.
- Outlook Therapeutics' 5-year Gross Profit high stood at $5.9 million for Q3 2019, and its period low was -$696,151 during Q1 2020.
- For the 3-year period, Outlook Therapeutics' Gross Profit averaged around $791,393, with its median value being $641,140 (2019).
- In the last 5 years, Outlook Therapeutics' Gross Profit skyrocketed by 658.34% in 2019 and then tumbled by 208.58% in 2020.
- Outlook Therapeutics' Gross Profit (Quarterly) stood at $303,140 in 2016, then soared by 154.63% to $771,890 in 2017, then skyrocketed by 38.31% to $1.1 million in 2018, then plummeted by 155.98% to -$597,665 in 2019, then plummeted by 100.33% to -$19,031 in 2020.
- Its Gross Profit was -$19,031 in Q3 2020, compared to -$443,624 in Q2 2020 and -$696,151 in Q1 2020.